Aptamer Market Type (DNA-Based Aptamers, RNA-Based Aptamers, XNA-Based Aptamers); Application (Diagnostics, Therapeutics Development, Research and Development, Other Applications); Technology (Selex, X-Aptamer, MARS Technique); End User (Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, Other End Users) and Geography: Global Market Size Estimates and Forecast (2022-2030)

The market crossed US$ 170 million mark in 2022 and is expected to hit US$ 370 million by 2030, recording a CAGR of 17.0% during the forecast period.

Aptamer market has been significantly growing with the growing number of clinical trials.

The rising number of clinical trials and research for designing aptamer-based therapeutic applications, raised awareness about the benefits of aptamers over monoclonal antibodies, increasing investment in pharmaceutical research, and increasing occurrence of severe and genetic disorders all contribute to the growth of the aptamers market. In 2021, Selex technology held the maximum share mainly due to increasing focus on developing technologies for aptamer selection.

Within the report, the market is segmented into type, application, technology, end-user, and geography. By type, the market is segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. On the basis of application, the market is segmented into diagnostics, therapeutics development, research and development, and other applications. Based on technology, the market is divided into Selex, X-aptamer, and MARS techniques. Based on end-user, the market is divided into academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations, and other end users. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report : Request Free Sample PDF

Growth in venture capital funding will empower the growth during the forecast period.

Aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) oligonucleotide molecules that stick to a specific target moiety. It has a variety of shapes due to its ability to form helices and single-stranded loops. There are many advantages of these small molecules in comparison to antibodies.

Several aptamer developing companies have identified the capability of aptamers for use in treatment and diagnostic applications. These players are now concentrating on securing funding from various investors to expand their offerings and strengthen their positions in the market. Thus, increasing venture capital funding is projected to drive market growth.

Rising awareness of the advantage of aptamers over antibodies is one of the major opportunities for market growth.

In comparison to antibodies, aptamers can significantly target small molecules. Furthermore, antibodies might cause an immunogenic response to the host, resulting in serious side-effects. In contrast, aptamers are non-immunogenic and safer. Aptamers also offer various advantages such as lower cost of production, ease of designing & synthesis, and high efficiency. These factors make them relatively economical. The scale-up is also enormous and therefore shows significant potential in the development of therapeutics.

Recent strategic developments in aptamer market

The aptamer market has undergone several significant developments, and a few of these have been mentioned below:

• In December 2020 — SomaLogic, Inc. raised USD 81 million from leading life sciences investors Casdin Capital, Farallon Capital Management, and Foresite Capital. It will support the commercialization of the company’s products in clinical and life science markets.
• In November 2020, SomaLogic, Inc. received funding of USD 121 million to assist the expansion and commercialization of its proteomics platform useful in the life science and clinical markets.
• In June 2018, Aptamer Group received USD 2.2 million from Meneldor and other overseas investors. These funds will be used to boost pre-clinical discovery programs involving the development of aptamer drug conjugates (ApDCs).

Several players drive the aptamer market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Vivonics Inc., TriLink BioTechnologies., SomaLogic, Inc., NeoVentures Biotechnology Inc., Base Pair Biotechnologies., APTATARGETS SL, Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC, KANEKA CORPORATION, IBA GmbH, AMS Biotechnology (Europe) Limited among others are the prominent players operating in the market.

Target audience for the report:

• Drug developing companies
• Contract development and manufacturing organization,
• Drug discovery-related associations, organizations, forums, and alliances
• Government bodies, such as regulating authorities and policymakers
• Venture capitalists, private equity firms, and start-up companies
• Drug distributors and sales firms
• End users of drug discovery
• Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

• Type:
  • DNA-based aptamer
  • RNA-based aptamer
  • XNA-based aptamer
• Application:
  • Diagnostics
  • Therapeutics development
  • Research and development
  • Other applications
• Technology:
  • Selex
  • X-Apatmers
  • MARS technique
• End User:
  • Academic and government research institutes
  • Biotechnology and pharmaceutical companies
  • Contract research organizations
  • Other end users
• Region
  • North America
  • Europe
  • Asia Pacific (APAC)
  • South & Central America
  • Middle East & Africa
• Companies profiled
  • Aptagen, LLC.
  • Aptamer Sciences INC.
  • Aptamer Sciences INC.
  • Aptus Biotech S.L.
  • Base Pair Biotechnologies, INC.
  • Somalogic, INC
  • Trilink Biotechnologies, INC.
  • Neoventures Biotechnology INC
  • Vivonics, INC..
  • Am Biotechnologies, LLC